Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology

Authors:
Apar Kishor P. Ganti Fred & Pamela Buffett Cancer Center;

Search for other papers by Apar Kishor P. Ganti in
Current site
Google Scholar
PubMed
Close
 MD
,
Billy W. Loo Jr. Stanford Cancer Institute;

Search for other papers by Billy W. Loo Jr. in
Current site
Google Scholar
PubMed
Close
 MD, PhD
,
Michael Bassetti University of Wisconsin Carbone Cancer Center;

Search for other papers by Michael Bassetti in
Current site
Google Scholar
PubMed
Close
 MD
,
Collin Blakely UCSF Helen Diller Family Comprehensive Cancer Center;

Search for other papers by Collin Blakely in
Current site
Google Scholar
PubMed
Close
 MD, PhD
,
Anne Chiang Yale Cancer Center/Smilow Cancer Hospital;

Search for other papers by Anne Chiang in
Current site
Google Scholar
PubMed
Close
 MD, PhD
,
Thomas A. D'Amico Duke Cancer Institute;

Search for other papers by Thomas A. D'Amico in
Current site
Google Scholar
PubMed
Close
 MD
,
Christopher D'Avella Abramson Cancer Center at the University of Pennsylvania;

Search for other papers by Christopher D'Avella in
Current site
Google Scholar
PubMed
Close
 MD
,
Afshin Dowlati Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute;

Search for other papers by Afshin Dowlati in
Current site
Google Scholar
PubMed
Close
 MD
,
Robert J. Downey Memorial Sloan Kettering Cancer Center;

Search for other papers by Robert J. Downey in
Current site
Google Scholar
PubMed
Close
 MD
,
Martin Edelman Fox Chase Cancer Center;

Search for other papers by Martin Edelman in
Current site
Google Scholar
PubMed
Close
 MD
,
Charles Florsheim Patient Advocate;

Search for other papers by Charles Florsheim in
Current site
Google Scholar
PubMed
Close
,
Kathryn A. Gold UC San Diego Moores Cancer Center;

Search for other papers by Kathryn A. Gold in
Current site
Google Scholar
PubMed
Close
 MD
,
Jonathan W. Goldman UCLA Jonsson Comprehensive Cancer Center;

Search for other papers by Jonathan W. Goldman in
Current site
Google Scholar
PubMed
Close
 MD
,
John C. Grecula The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute;

Search for other papers by John C. Grecula in
Current site
Google Scholar
PubMed
Close
 MD
,
Christine Hann The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;

Search for other papers by Christine Hann in
Current site
Google Scholar
PubMed
Close
 MD, PhD
,
Wade Iams Vanderbilt-Ingram Cancer Center;

Search for other papers by Wade Iams in
Current site
Google Scholar
PubMed
Close
 MD
,
Puneeth Iyengar UT Southwestern Simmons Comprehensive Cancer Center;

Search for other papers by Puneeth Iyengar in
Current site
Google Scholar
PubMed
Close
 MD, PhD
,
Karen Kelly UC Davis Comprehensive Cancer Center;

Search for other papers by Karen Kelly in
Current site
Google Scholar
PubMed
Close
 MD
,
Maya Khalil O'Neal Comprehensive Cancer Center at UAB;

Search for other papers by Maya Khalil in
Current site
Google Scholar
PubMed
Close
 MD
,
Marianna Koczywas City of Hope National Medical Center;

Search for other papers by Marianna Koczywas in
Current site
Google Scholar
PubMed
Close
 MD
,
Robert E. Merritt The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute;

Search for other papers by Robert E. Merritt in
Current site
Google Scholar
PubMed
Close
 MD
,
Nisha Mohindra Robert H. Lurie Comprehensive Cancer Center of Northwestern University;

Search for other papers by Nisha Mohindra in
Current site
Google Scholar
PubMed
Close
 MD
,
Julian Molina Mayo Clinic Cancer Center;

Search for other papers by Julian Molina in
Current site
Google Scholar
PubMed
Close
 MD, PhD
,
Cesar Moran The University of Texas MD Anderson Cancer Center;

Search for other papers by Cesar Moran in
Current site
Google Scholar
PubMed
Close
 MD
,
Saraswati Pokharel Roswell Park Comprehensive Cancer Center;

Search for other papers by Saraswati Pokharel in
Current site
Google Scholar
PubMed
Close
 MD
,
Sonam Puri Huntsman Cancer Institute at the University of Utah;

Search for other papers by Sonam Puri in
Current site
Google Scholar
PubMed
Close
 MD
,
Angel Qin University of Michigan Rogel Cancer Center;

Search for other papers by Angel Qin in
Current site
Google Scholar
PubMed
Close
 MD
,
Chad Rusthoven University of Colorado Cancer Center;

Search for other papers by Chad Rusthoven in
Current site
Google Scholar
PubMed
Close
 MD
,
Jacob Sands Dana Farber/Brigham and Women's Cancer Center;

Search for other papers by Jacob Sands in
Current site
Google Scholar
PubMed
Close
 MD
,
Rafael Santana-Davila Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance;

Search for other papers by Rafael Santana-Davila in
Current site
Google Scholar
PubMed
Close
 MD
,
Michael Shafique Moffitt Cancer Center;

Search for other papers by Michael Shafique in
Current site
Google Scholar
PubMed
Close
 MD
,
Saiama N. Waqar Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine;

Search for other papers by Saiama N. Waqar in
Current site
Google Scholar
PubMed
Close
 MBBS, MSCI
,
Kristina M. Gregory National Comprehensive Cancer Network.

Search for other papers by Kristina M. Gregory in
Current site
Google Scholar
PubMed
Close
 RN, MSN, OCN
, and
Miranda Hughes National Comprehensive Cancer Network.

Search for other papers by Miranda Hughes in
Current site
Google Scholar
PubMed
Close
 PhD
Restricted access

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Small Cell Lung Cancer (SCLC) provide recommended management for patients with SCLC, including diagnosis, primary treatment, surveillance for relapse, and subsequent treatment. This selection for the journal focuses on metastatic (known as extensive-stage) SCLC, which is more common than limited-stage SCLC. Systemic therapy alone can palliate symptoms and prolong survival in most patients with extensive-stage disease. Smoking cessation counseling and intervention should be strongly promoted in patients with SCLC and other high-grade neuroendocrine carcinomas. The “Summary of the Guidelines Updates” section in the SCLC algorithm outlines the most recent revisions for the 2022 update, which are described in greater detail in this revised Discussion text.

Individual Disclosures for the NCCN Small Cell Lung Cancer Panel

T1

  • Collapse
  • Expand
  • 1.

    Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2018, based on November 2020 SEER data submission, posted to the SEER web site, April 2021. Bethesda, MD: National Cancer Institute. Available at: https://seer.cancer.gov/csr/1975_2018/.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006;24:45394544.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Siegel RL, Miller KD, Fuchs HE, et al. Cancer Statistics, 2021. CA Cancer J Clin 2021;71:733.

  • 4.

    Pesch B, Kendzia B, Gustavsson P, et al. Cigarette smoking and lung cancer--relative risk estimates for the major histological types from a pooled analysis of case-control studies. Int J Cancer 2012;131:12101219.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Jett JR, Schild SE, Kesler KA, et al. Treatment of small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013;143:e400Se419S.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Kalemkerian GP. Advances in the treatment of small-cell lung cancer. Semin Respir Crit Care Med 2011;32:94101.

  • 7.

    Stinchcombe TE, Gore EM. Limited-stage small cell lung cancer: current chemoradiotherapy treatment paradigms. Oncologist 2010;15:187195.

  • 8.

    Demedts IK, Vermaelen KY, van Meerbeeck JP. Treatment of extensive-stage small cell lung carcinoma: current status and future prospects. Eur Respir J 2010;35:202215.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Yang CJ, Chan DY, Shah SA, et al. Long-term survival after surgery compared with concurrent chemoradiation for node-negative small cell lung cancer. Ann Surg 2018;268:11051112.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Shioyama Y, Onishi H, Takayama K, et al. Clinical outcomes of stereotactic body radiotherapy for patients with stage I small-cell lung cancer: analysis of a subset of the Japanese Radiological Society multi-institutional SBRT study group database. Technol Cancer Res Treat 2018;17:1533033818783904.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11.

    Verma V, Simone CB II, Allen PK, et al. Multi-institutional experience of stereotactic ablative radiation therapy for stage I small cell lung cancer. Int J Radiat Oncol Biol Phys 2017;97:362371.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Yu JB, Decker RH, Detterbeck FC, et al. Surveillance epidemiology and end results evaluation of the role of surgery for stage I small cell lung cancer. J Thorac Oncol 2010;5:215219.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13.

    Leone FT, Evers-Casey S, Toll BA, et al. Treatment of tobacco use in lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013;143:e61Se77S.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14.

    Videtic GMM, Stitt LW, Dar AR, et al. Continued cigarette smoking by patients receiving concurrent chemoradiotherapy for limited-stage small-cell lung cancer is associated with decreased survival. J Clin Oncol 2003;21:15441549.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 15.

    Demetri G, Elias A, Gershenson D, et al. NCCN Small-Cell Lung Cancer Practice Guidelines. Oncology (Williston Park) 1996; 10(11, Suppl)179194.

  • 16.

    Cuffe S, Moua T, Summerfield R, et al. Characteristics and outcomes of small cell lung cancer patients diagnosed during two lung cancer computed tomographic screening programs in heavy smokers. J Thorac Oncol 2011;6:818822.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 17.

    Aberle DR, Adams AM, Berg CD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011;365:395409.

  • 18.

    Thomas A, Pattanayak P, Szabo E, et al. Characteristics and Outcomes of Small Cell Lung Cancer Detected by CT Screening. Chest 2018;154:12841290.

  • 19.

    Kondo R, Yoshida K, Kawakami S, et al. Different efficacy of CT screening for lung cancer according to histological type: analysis of Japanese-smoker cases detected using a low-dose CT screen. Lung Cancer 2011;74:433440.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 20.

    Rivera MP, Mehta AC, Wahidi MM. Establishing the diagnosis of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013;143:e142Se165S.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 21.

    Travis WD. Advances in neuroendocrine lung tumors. Ann Oncol 2010;21(Suppl 7):vii65vii71.

  • 22.

    Renshaw AA, Haja J, Lozano RL, et al. Distinguishing carcinoid tumor from small cell carcinoma of the lung: correlating cytologic features and performance in the College of American Pathologists Non-Gynecologic Cytology Program. Arch Pathol Lab Med 2005;129:614618.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 23.

    Gandhi L, Johnson BE. Paraneoplastic syndromes associated with small cell lung cancer. J Natl Compr Canc Netw 2006;4:631638.

  • 24.

    Kazarian M, Laird-Offringa IA. Small-cell lung cancer-associated autoantibodies: potential applications to cancer diagnosis, early detection, and therapy. Mol Cancer 2011;10:33.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 25.

    Marchioli CC, Graziano SL. Paraneoplastic syndromes associated with small cell lung cancer. Chest Surg Clin N Am 1997;7:6580.

  • 26.

    Titulaer MJ, Wirtz PW, Willems LN, et al. Screening for small-cell lung cancer: a follow-up study of patients with Lambert-Eaton myasthenic syndrome. J Clin Oncol 2008;26:42764281.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 27.

    Meriney SD, Hulsizer SC, Lennon VA, et al. Lambert-Eaton myasthenic syndrome immunoglobulins react with multiple types of calcium channels in small-cell lung carcinoma. Ann Neurol 1996;40:739749.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 28.

    Graus F, Keime-Guibert F, Reñe R, et al. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain 2001;124:11381148.

  • 29.

    Delisle L, Boyer MJ, Warr D, et al. Ectopic corticotropin syndrome and small-cell carcinoma of the lung. Clinical features, outcome, and complications. Arch Intern Med 1993;153:746752.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 30.

    Johnson BE, Chute JP, Rushin J, et al. A prospective study of patients with lung cancer and hyponatremia of malignancy. Am J Respir Crit Care Med 1997;156:16691678.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 31.

    Castillo JJ, Vincent M, Justice E. Diagnosis and management of hyponatremia in cancer patients. Oncologist 2012;17:756765.

  • 32.

    Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006;355:20992112.

  • 33.

    Verbalis JG, Zeltser D, Smith N, et al. Assessment of the efficacy and safety of intravenous conivaptan in patients with euvolaemic hyponatraemia: subgroup analysis of a randomized, controlled study. Clin Endocrinol (Oxf) 2008;69:159168.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 34.

    Rudin CM, Brambilla E, Faivre-Finn C, et al. Small-cell lung cancer. Nat Rev Dis Primers 2021;7:3.

  • 35.

    Raso MG, Bota-Rabassedas N, Wistuba II. Pathology and classification of SCLC. Cancers (Basel) 2021;13:820.

  • 36.

    Schnabel PA, Junker K. [Pulmonary neuroendocrine tumors in the new WHO 2015 classification: Start of breaking new grounds?]. Pathologe 2015;36:283292.

  • 37.

    Travis WD, Brambilla E, Burke AP, et al. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart, 4th Ed. Geneva, Switzerland: World Health Organization; 2015.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 38.

    Travis WD, Brambilla E, Burke AP, et al. Introduction to the 2015 World Health Organization classification of tumors of the lung, pleura, thymus, and heart. J Thorac Oncol 2015;10:12401242.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 39.

    Travis WD, Brambilla E, Nicholson AG, et al. The 2015 World Health Organization Classification of Lung Tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol 2015;10:12431260.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 40.

    Travis WD. Pathology and diagnosis of neuroendocrine tumors: lung neuroendocrine. Thorac Surg Clin 2014;24:257266.

  • 41.

    Zakowski MF. Pathology of small cell carcinoma of the lung. Semin Oncol 2003;30:38.

  • 42.

    Nicholson SA, Beasley MB, Brambilla E, et al. Small cell lung carcinoma (SCLC): a clinicopathologic study of 100 cases with surgical specimens. Am J Surg Pathol 2002;26:11841197.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 43.

    Pelosi G, Rodriguez J, Viale G, et al. Typical and atypical pulmonary carcinoid tumor overdiagnosed as small-cell carcinoma on biopsy specimens: a major pitfall in the management of lung cancer patients. Am J Surg Pathol 2005;29:179187.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 44.

    Brenner B, Tang LH, Klimstra DS, et al. Small-cell carcinomas of the gastrointestinal tract: a review. J Clin Oncol 2004;22:27302739.

  • 45.

    Galanis E, Frytak S, Lloyd RV. Extrapulmonary small cell carcinoma. Cancer 1997;79:17291736.

  • 46.

    Bellizzi AM. Immunohistochemistry in the diagnosis and classification of neuroendocrine neoplasms: what can brown do for you? Hum Pathol 2020;96:833.

  • 47.

    Thunnissen E, Borczuk AC, Flieder DB, et al. The use of immunohistochemistry improves the diagnosis of small cell lung cancer and its differential diagnosis. An international reproducibility study in a demanding set of cases. J Thorac Oncol 2017;12:334346.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 48.

    Rindi G, Klersy C, Inzani F, et al. Grading the neuroendocrine tumors of the lung: an evidence-based proposal. Endocr Relat Cancer 2013;21:116.

  • 49.

    Masai K, Tsuta K, Kawago M, et al. Expression of squamous cell carcinoma markers and adenocarcinoma markers in primary pulmonary neuroendocrine carcinomas. Appl Immunohistochem Mol Morphol 2013;21:292297.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 50.

    Ordóñez NG. Value of thyroid transcription factor-1 immunostaining in distinguishing small cell lung carcinomas from other small cell carcinomas. Am J Surg Pathol 2000;24:12171223.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 51.

    Kaufmann O, Dietel M. Expression of thyroid transcription factor-1 in pulmonary and extrapulmonary small cell carcinomas and other neuroendocrine carcinomas of various primary sites. Histopathology 2000;36:415420.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 52.

    Rekhtman N, Pietanza CM, Sabari J, et al. Pulmonary large cell neuroendocrine carcinoma with adenocarcinoma-like features: napsin A expression and genomic alterations. Mod Pathol 2018;31:111121.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 53.

    Rooper LM, Sharma R, Li QK, et al. INSM1 demonstrates superior performance to the individual and combined use of synaptophysin, chromogranin and CD56 for diagnosing neuroendocrine tumors of the thoracic cavity. Am J Surg Pathol 2017;41:15611569.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 54.

    Sakakibara R, Kobayashi M, Takahashi N, et al. Insulinoma-associated protein 1 (INSM1) is a better marker for the diagnosis and prognosis estimation of small cell lung carcinoma than neuroendocrine phenotype markers such as chromogranin A, synaptophysin, and CD56. Am J Surg Pathol 2020;44:757764.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 55.

    Guinee DG, Jr., Fishback NF, Koss MN, et al. The spectrum of immunohistochemical staining of small-cell lung carcinoma in specimens from transbronchial and open-lung biopsies. Am J Clin Pathol 1994;102:406414.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 56.

    Rindi G, Klimstra DS, Abedi-Ardekani B, et al. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod Pathol 2018;31:17701786.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 57.

    Pelosi G, Rindi G, Travis WD, et al. Ki-67 antigen in lung neuroendocrine tumors: unraveling a role in clinical practice. J Thorac Oncol 2014;9:273284.

  • 58.

    Qin J, Lu H. Combined small-cell lung carcinoma. OncoTargets Ther 2018;11:35053511.

  • 59.

    Marcoux N, Gettinger SN, O’Kane G, et al. EGFR-mutant adenocarcinomas that transform to small-cell lung cancer and other neuroendocrine carcinomas: clinical outcomes. J Clin Oncol 2019;37:278285.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 60.

    Sehgal K, Varkaris A, Viray H, et al. Small cell transformation of non-small cell lung cancer on immune checkpoint inhibitors: uncommon or under-recognized? J Immunother Cancer 2020;8:e000697.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 61.

    George J, Lim JS, Jang SJ, et al. Comprehensive genomic profiles of small cell lung cancer. Nature 2015;524:4753.

  • 62.

    Su S, Zou JJ, Zeng YY, et al. Tumor mutational burden and genomic alterations in Chinese small cell lung cancer measured by whole-exome sequencing. BioMed Res Int 2019;2019:6096350.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 63.

    Wakuda K, Kenmotsu H, Serizawa M, et al. Molecular profiling of small cell lung cancer in a Japanese cohort. Lung Cancer 2014;84:139144.

  • 64.

    Liguori NR, Lee Y, Borges W, et al. Absence of biomarker-driven treatment options in small cell lung cancer, and selected preclinical candidates for next generation combination therapies. Front Pharmacol 2021;12:747180.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 65.

    Kalemkerian GP, Gadgeel SM. Modern staging of small cell lung cancer. J Natl Compr Canc Netw 2013;11:99104.

  • 66.

    Micke P, Faldum A, Metz T, et al. Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer--what limits limited disease? Lung Cancer 2002;37:271276.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 67.

    Kalemkerian GP. Staging and imaging of small cell lung cancer. Cancer Imaging 2012;11:253258.

  • 68.

    Amin MB, Greene FL, Byrd DR, et al. AJCC Cancer Staging Manual, 8th Ed. New York, NY: Springer International Publishing; 2016.

  • 69.

    Nicholson AG, Chansky K, Crowley J, et al. The International Association for the Study of Lung Cancer lung cancer staging project: proposals for the revision of the clinical and pathologic staging of small cell lung cancer in the forthcoming eighth edition of the TNM Classification for Lung Cancer. J Thorac Oncol 2016;11:300311.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 70.

    Seute T, Leffers P, ten Velde GP, et al. Detection of brain metastases from small cell lung cancer: consequences of changing imaging techniques (CT versus MRI). Cancer 2008;112:18271834.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 71.

    Podoloff DA, Ball DW, Ben-Josef E, et al. NCCN task force: clinical utility of PET in a variety of tumor types. J Natl Compr Canc Netw 2009;7(Suppl 2):S1S26.

  • 72.

    Bradley JD, Dehdashti F, Mintun MA, et al. Positron emission tomography in limited-stage small-cell lung cancer: a prospective study. J Clin Oncol 2004;22:32483254.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 73.

    Fischer BM, Mortensen J, Langer SW, et al. A prospective study of PET/CT in initial staging of small-cell lung cancer: comparison with CT, bone scintigraphy and bone marrow analysis. Ann Oncol 2007;18:338345.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 74.

    Brink I, Schumacher T, Mix M, et al. Impact of [18F]FDG-PET on the primary staging of small-cell lung cancer. Eur J Nucl Med Mol Imaging 2004;31:16141620.

  • 75.

    Kamel EM, Zwahlen D, Wyss MT, et al. Whole-body (18)F-FDG PET improves the management of patients with small cell lung cancer. J Nucl Med 2003;44:19111917.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 76.

    Rintoul RC, Tournoy KG, El Daly H, et al. EBUS-TBNA for the clarification of PET positive intra-thoracic lymph nodes-an international multi-centre experience. J Thorac Oncol 2009;4:4448.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 77.

    Medford AR, Bennett JA, Free CM, et al. Mediastinal staging procedures in lung cancer: EBUS, TBNA and mediastinoscopy. Curr Opin Pulm Med 2009;15:334342.

  • 78.

    Foster NR, Mandrekar SJ, Schild SE, et al. Prognostic factors differ by tumor stage for small cell lung cancer: a pooled analysis of North Central Cancer Treatment Group trials. Cancer 2009;115:27212731.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 79.

    Albain KS, Crowley JJ, LeBlanc M, et al. Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base. J Clin Oncol 1990;8:15631574.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 80.

    Hatfield LA, Huskamp HA, Lamont EB. Survival and toxicity after cisplatin plus etoposide versus carboplatin plus etoposide for extensive-stage small-cell lung cancer in elderly patients. J Oncol Pract 2016;12:666673.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 81.

    Bishop JF, Raghavan D, Stuart-Harris R, et al. Carboplatin (CBDCA, JM-8) and VP-16-213 in previously untreated patients with small-cell lung cancer. J Clin Oncol 1987;5:15741578.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 82.

    Skarlos DV, Samantas E, Kosmidis P, et al. Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group study. Ann Oncol 1994;5:601607.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 83.

    Okamoto H, Watanabe K, Kunikane H, et al. Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702. Br J Cancer 2007;97:162169.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 84.

    Rossi A, Di Maio M, Chiodini P, et al. Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. J Clin Oncol 2012;30:16921698.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 85.

    Liu SV, Reck M, Mansfield AS, et al. Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133). J Clin Oncol 2021;39:619630.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 86.

    Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet 2019;394:19291939.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 87.

    Horn L, Mansfield AS, Szczęsna A, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med 2018;379:22202229.

  • 88.

    Postmus PE, Haaxma-Reiche H, Gregor A, et al. Brain-only metastases of small cell lung cancer; efficacy of whole brain radiotherapy: an EORTC phase II study. Radiother Oncol 1998;46:2932.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 89.

    Goldman JW, Dvorkin M, Chen Y, et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2021;22:5165.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 90.

    Paz-Ares L, Chen Y, Reinmuth N, et al. LBA61 - Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): 3-year overall survival update from the phase III CASPIAN study [abstract]. Ann Oncol 2021;32(suppl_5):S1283.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 91.

    Mathieu L, Shah S, Pai-Scherf L, et al. FDA Approval Summary: atezolizumab and durvalumab in combination with platinum-based chemotherapy in extensive stage small cell lung cancer. Oncologist 2021;26:433438.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 92.

    Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002;346:8591.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 93.

    Lara PN, Jr., Natale R, Crowley J, et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol 2009;27:25302535.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 94.

    Hanna N, Bunn PA, Jr, Langer C, et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 2006;24:20382043.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 95.

    Hermes A, Bergman B, Bremnes R, et al. Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial. J Clin Oncol 2008;26:42614267.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 96.

    Lima JP, dos Santos LV, Sasse EC, et al. Camptothecins compared with etoposide in combination with platinum analog in extensive stage small cell lung cancer: systematic review with meta-analysis. J Thorac Oncol 2010;5:19861993.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 97.

    Reck M, Luft A, Szczesna A, et al. Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer. J Clin Oncol 2016;34:37403748.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 98.

    Petrioli R, Roviello G, Laera L, et al. Cisplatin, etoposide, and bevacizumab regimen followed by oral etoposide and bevacizumab maintenance treatment in patients with extensive-stage small cell lung cancer: a single-institution experience. Clin Lung Cancer 2015;16:e229e234.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 99.

    Spigel DR, Townley PM, Waterhouse DM, et al. Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial. J Clin Oncol 2011;29:22152222.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 100.

    Spigel DR, Greco FA, Zubkus JD, et al. Phase II trial of irinotecan, carboplatin, and bevacizumab in the treatment of patients with extensive-stage small-cell lung cancer. J Thorac Oncol 2009;4:15551560.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 101.

    Horn L, Dahlberg SE, Sandler AB, et al. Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501. J Clin Oncol 2009;27:60066011.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 102.

    Tiseo M, Boni L, Ambrosio F, et al. Italian, multicenter, phase III, randomized study of cisplatin plus etoposide with or without bevacizumab as first-line treatment in extensive-disease small-cell lung cancer: the GOIRC-AIFA FARM6PMFJM trial. J Clin Oncol 2017;35:12811287.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 103.

    Pujol JL, Lavole A, Quoix E, et al. Randomized phase II-III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial. Ann Oncol 2015;26:908914.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 104.

    Loehrer PJ, Sr., Ansari R, Gonin R, et al. Cisplatin plus etoposide with and without ifosfamide in extensive small-cell lung cancer: a Hoosier Oncology Group study. J Clin Oncol 1995;13:25942599.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 105.

    Pujol JL, Daurès JP, Rivière A, et al. Etoposide plus cisplatin with or without the combination of 4′-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: a French Federation of Cancer Institutes multicenter phase III randomized study. J Natl Cancer Inst 2001;93:300308.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 106.

    Miyamoto H, Nakabayashi T, Isobe H, et al. A phase III comparison of etoposide/cisplatin with or without added ifosfamide in small-cell lung cancer. Oncology 1992;49:431435.

  • 107.

    Berghmans T, Scherpereel A, Meert AP, et al. A phase III randomized study comparing a chemotherapy with cisplatin and etoposide to a etoposide regimen without cisplatin for patients with extensive small-cell lung cancer. Front Oncol 2017;7:217.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 108.

    Jalal SI, Lavin P, Lo G, et al. Carboplatin and etoposide with or without palifosfamide in untreated extensive-stage small-cell lung cancer: a multicenter, adaptive, randomized phase III study (MATISSE). J Clin Oncol 2017;35:26192623.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 109.

    Niell HB, Herndon JE II, Miller AA, et al. Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732. J Clin Oncol 2005;23:37523759.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 110.

    Schiller JH, Adak S, Cella D, et al. Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593─a phase III trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2001;19:21142122.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 111.

    Zhou H, Zeng C, Wei Y, et al. Duration of chemotherapy for small cell lung cancer: a meta-analysis. PLoS One 2013;8:e73805.

  • 112.

    Goldie JH, Coldman AJ. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979;63:17271733.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 113.

    Fukuoka M, Furuse K, Saijo N, et al. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 1991;83:855861.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 114.

    Roth BJ, Johnson DH, Einhorn LH, et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 1992;10:282291.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 115.

    Miles DW, Earl HM, Souhami RL, et al. Intensive weekly chemotherapy for good-prognosis patients with small-cell lung cancer. J Clin Oncol 1991;9:280285.

  • 116.

    Murray N, Gelmon K, Shah A. Potential for long-term survival in extensive stage small-cell lung cancer (ESCLC) with CODE chemotherapy and radiotherapy [abstract]. Lung Cancer 1994;11 (Suppl 1):99 Abstract 377.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 117.

    Sculier JP, Paesmans M, Bureau G, et al. Multiple-drug weekly chemotherapy versus standard combination regimen in small-cell lung cancer: a phase III randomized study conducted by the European Lung Cancer Working Party. J Clin Oncol 1993;11:18581865.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 118.

    Souhami RL, Rudd R, Ruiz de Elvira MC, et al. Randomized trial comparing weekly versus 3-week chemotherapy in small-cell lung cancer: a Cancer Research Campaign trial. J Clin Oncol 1994;12:18061813.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 119.

    Fukuoka M, Masuda N, Negoro S, et al. CODE chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer. Br J Cancer 1997;75:306309.

  • 120.

    Murray N, Livingston RB, Shepherd FA, et al. Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group. J Clin Oncol 1999;17:23002308.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 121.

    Cohen MH, Creaven PJ, Fossieck BE, Jr., et al. Intensive chemotherapy of small cell bronchogenic carcinoma. Cancer Treat Rep 1977;61:349354.

  • 122.

    Johnson DH, Einhorn LH, Birch R, et al. A randomized comparison of high-dose versus conventional-dose cyclophosphamide, doxorubicin, and vincristine for extensive-stage small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 1987;5:17311738.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 123.

    Ihde DC, Mulshine JL, Kramer BS, et al. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. J Clin Oncol 1994;12:20222034.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 124.

    Arriagada R, Le Chevalier T, Pignon JP, et al. Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer. N Engl J Med 1993;329:18481852.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 125.

    Thatcher N, Girling DJ, Hopwood P, et al. Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a British Medical Research Council Multicenter Randomized Trial. J Clin Oncol 2000;18:395404.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 126.

    Klasa RJ, Murray N, Coldman AJ. Dose-intensity meta-analysis of chemotherapy regimens in small-cell carcinoma of the lung. J Clin Oncol 1991;9:499508.

  • 127.

    Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991;325:164170.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 128.

    Berghmans T, Paesmans M, Lafitte JJ, et al. Role of granulocyte and granulocyte-macrophage colony-stimulating factors in the treatment of small-cell lung cancer: a systematic review of the literature with methodological assessment and meta-analysis. Lung Cancer 2002;37:115123.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 129.

    Sculier JP, Paesmans M, Lecomte J, et al. A three-arm phase III randomised trial assessing, in patients with extensive-disease small-cell lung cancer, accelerated chemotherapy with support of haematological growth factor or oral antibiotics. Br J Cancer 2001;85:14441451.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 130.

    Ferrarotto R, Anderson I, Medgyasszay B, et al. Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy-induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomized phase 2 trials. Cancer Med 2021;10:57485756.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 131.

    Hussein M, Maglakelidze M, Richards DA, et al. Myeloprotective effects of trilaciclib among patients with small cell lung cancer at increased risk of chemotherapy-induced myelosuppression: pooled results from three phase 2, randomized, double-blind, placebo-controlled studies. Cancer Manag Res 2021;13:62076218.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 132.

    Weiss J, Goldschmidt J, Andric Z, et al. Effects of trilaciclib on chemotherapy-induced myelosuppression and patient-reported outcomes in patients with extensive-stage small cell lung cancer: pooled results from three phase II randomized, double-blind, placebo-controlled studies. Clin Lung Cancer 2021;22:449460.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 133.

    Hart LL, Ferrarotto R, Andric ZG, et al. Myelopreservation with trilaciclib in patients receiving topotecan for small cell lung cancer: results from a randomized, double-blind, placebo-controlled phase II study. Adv Ther 2021;38:350365.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 134.

    Hurria A, Kris MG. Management of lung cancer in older adults. CA Cancer J Clin 2003;53:325341.

  • 135.

    Christodoulou M, Blackhall F, Mistry H, et al. Compliance and outcome of elderly patients treated in the concurrent once-daily versus twice-daily radiotherapy (CONVERT) trial. J Thorac Oncol 2019;14:6371.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 136.

    Corso CD, Rutter CE, Park HS, et al. Role of chemoradiotherapy in elderly patients with limited-stage small-cell lung cancer. J Clin Oncol 2015;33:42404246.

  • 137.

    Gridelli C, Casaluce F, Sgambato A, et al. Treatment of limited-stage small cell lung cancer in the elderly, chemotherapy vs. sequential chemoradiotherapy vs. concurrent chemoradiotherapy: that’s the question. Transl Lung Cancer Res 2016;5:150154.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 138.

    Girling DJ. Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: a stopped multicentre randomised trial. Lancet 1996;348:563566.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 139.

    Souhami RL, Spiro SG, Rudd RM, et al. Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy. J Natl Cancer Inst 1997;89:577580.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 140.

    Neubauer M, Schwartz J, Caracandas J, et al. Results of a phase II study of weekly paclitaxel plus carboplatin in patients with extensive small-cell lung cancer with Eastern Cooperative Oncology Group Performance Status of 2, or age > or = 70 years. J Clin Oncol 2004;22:18721877.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 141.

    Westeel V, Murray N, Gelmon K, et al. New combination of the old drugs for elderly patients with small-cell lung cancer: a phase II study of the PAVE regimen. J Clin Oncol 1998;16:19401947.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 142.

    Okamoto H, Watanabe K, Nishiwaki Y, et al. Phase II study of area under the plasma-concentration-versus-time curve-based carboplatin plus standard-dose intravenous etoposide in elderly patients with small-cell lung cancer. J Clin Oncol 1999;17:35403545.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 143.

    Matsui K, Masuda N, Yana T, et al. Carboplatin calculated with Chatelut’s formula plus etoposide for elderly patients with small-cell lung cancer. Intern Med 2001;40:603606.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 144.

    Murray N, Grafton C, Shah A, et al. Abbreviated treatment for elderly, infirm, or noncompliant patients with limited-stage small-cell lung cancer. J Clin Oncol 1998;16:33233328.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 145.

    Wolfson AH, Bae K, Komaki R, et al. Primary analysis of a phase II randomized trial Radiation Therapy Oncology Group (RTOG) 0212: impact of different total doses and schedules of prophylactic cranial irradiation on chronic neurotoxicity and quality of life for patients with limited-disease small-cell lung cancer. Int J Radiat Oncol Biol Phys 2011;81:7784.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 146.

    Le Péchoux C, Laplanche A, Faivre-Finn C, et al. Clinical neurological outcome and quality of life among patients with limited small-cell cancer treated with two different doses of prophylactic cranial irradiation in the intergroup phase III trial (PCI99-01, EORTC 22003-08004, RTOG 0212 and IFCT 99-01). Ann Oncol 2011;22:11541163.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 147.

    Farooqi AS, Holliday EB, Allen PK, et al. Prophylactic cranial irradiation after definitive chemoradiotherapy for limited-stage small cell lung cancer: do all patients benefit? Radiother Oncol 2017;122:307312.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 148.

    Lok BH, Ma J, Foster A, et al. Factors influencing the utilization of prophylactic cranial irradiation in patients with limited-stage small cell lung cancer. Adv Radiat Oncol 2017;2:548554.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 149.

    Damhuis RAM, Senan S, Belderbos JS. Usage of prophylactic cranial irradiation in elderly patients with small-cell lung cancer. Clin Lung Cancer 2018;19:e263e267.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 150.

    Hurwitz JL, McCoy F, Scullin P, et al. New advances in the second-line treatment of small cell lung cancer. Oncologist 2009;14:986994.

  • 151.

    Schneider BJ. Management of recurrent small cell lung cancer. J Natl Compr Canc Netw 2008;6:323331.

  • 152.

    Manapov F, Klöcking S, Niyazi M, et al. Timing of failure in limited disease (stage I-III) small-cell lung cancer patients treated with chemoradiotherapy: a retrospective analysis. Tumori 2013;99:656660.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 153.

    Johnson BE, Linnoila RI, Williams JP, et al. Risk of second aerodigestive cancers increases in patients who survive free of small-cell lung cancer for more than 2 years. J Clin Oncol 1995;13:101111.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 154.

    Johnson BE. Second lung cancers in patients after treatment for an initial lung cancer. J Natl Cancer Inst 1998;90:13351345.

  • 155.

    Richardson GE, Tucker MA, Venzon DJ, et al. Smoking cessation after successful treatment of small-cell lung cancer is associated with fewer smoking-related second primary cancers. Ann Intern Med 1993;119:383390.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 156.

    Kawahara M, Ushijima S, Kamimori T, et al. Second primary tumours in more than 2-year disease-free survivors of small-cell lung cancer in Japan: the role of smoking cessation. Br J Cancer 1998;78:409412.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 157.

    Parsons A, Daley A, Begh R, et al. Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis. BMJ 2010;340(jan21 1):b5569.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 158.

    Owonikoko TK, Behera M, Chen Z, et al. A systematic analysis of efficacy of second-line chemotherapy in sensitive and refractory small-cell lung cancer. J Thorac Oncol 2012;7:866872.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 159.

    Dingemans AC, Früh M, Ardizzoni A, et al. Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up⋆. Ann Oncol 2021;32:839853.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 160.

    Trigo J, Subbiah V, Besse B, et al. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. Lancet Oncol 2020;21:645654.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 161.

    Subbiah V, Paz-Ares L, Besse B, et al. Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment. Lung Cancer 2020;150:9096.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 162.

    Lammers PE, Shyr Y, Li CI, et al. Phase II study of bendamustine in relapsed chemotherapy sensitive or resistant small-cell lung cancer. J Thorac Oncol 2014;9:559562.

  • 163.

    Pietanza MC, Kadota K, Huberman K, et al. Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker. Clin Cancer Res 2012;18:11381145.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 164.

    Cheng S, Evans WK, Stys-Norman D, et al. Chemotherapy for relapsed small cell lung cancer: a systematic review and practice guideline. J Thorac Oncol 2007;2:348354.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 165.

    Masters GA, Declerck L, Blanke C, et al. Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: Eastern Cooperative Oncology Group Trial 1597. J Clin Oncol 2003;21:15501555.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 166.

    von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999;17:658667.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 167.

    O’Brien ME, Ciuleanu TE, Tsekov H, et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 2006;24:54415447.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 168.

    Eckardt JR, von Pawel J, Pujol JL, et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol 2007;25:20862092.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 169.

    Huber RM, Reck M, Gosse H, et al. Efficacy of a toxicity-adjusted topotecan therapy in recurrent small cell lung cancer. Eur Respir J 2006;27:11831189.

  • 170.

    Shah C, Ready N, Perry M, et al. A multi-center phase II study of weekly topotecan as second-line therapy for small cell lung cancer. Lung Cancer 2007;57:8488.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 171.

    Shipley DL, Hainsworth JD, Spigel DR, et al. Topotecan: weekly intravenous (IV) schedule similar to standard 5-day IV schedule as second-line therapy for relapsed small cell lung cancer (SCLC)–a Minnie Pearl Cancer Research Network phase II trial [abstract]. J Clin Oncol 2006;24 (Suppl 18):Abstract 7083.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 172.

    Ready NE, Ott PA, Hellmann MD, et al. Nivolumab monotherapy and nivolumab plus ipilimumab in recurrent small cell lung cancer: results from the CheckMate 032 randomized cohort. J Thorac Oncol 2020;15:426435.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 173.

    Antonia SJ, López-Martin JA, Bendell J, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol 2016;17:883895.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 174.

    Ott PA, Elez E, Hiret S, et al. Pembrolizumab in patients with rxtensive-stage small-cell lung cancer: results from the phase Ib KEYNOTE-028 Study. J Clin Oncol 2017;35:38233829.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 175.

    Horn L, Reck M, Spigel DR. The future of immunotherapy in the treatment of small cell lung cancer. Oncologist 2016;21:910921.

  • 176.

    Spigel DR, Vicente D, Ciuleanu TE, et al. Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331⋆. Ann Oncol 2021;32:631641.

  • 177.

    Reck M, Vicente D, Ciuleanu T, et al. LBA5: Efficacy and safety of nivolumab (nivo) monotherapy versus chemotherapy (chemo) in recurrent small cell lung cancer (SCLC): Results from CheckMate 331. [abstract] Ann Oncol 2018;29:43.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 178.

    Keeping ST, Cope S, Chan K, et al. Comparative effectiveness of nivolumab versus standard of care for third-line patients with small-cell lung cancer. J Comp Eff Res 2020;9:12751284.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 179.

    Hellmann MD, Ott PA, Zugazagoitia J, et al. Nivolumab (nivo) ± ipilimumab (ipi) in advanced small-cell lung cancer (SCLC): First report of a randomized expansion cohort from CheckMate 032. [abstract] J Clin Oncol 2017;35(15_suppl):35. (Abstract 8503)

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 180.

    Chung HC, Piha-Paul SA, Lopez-Martin J, et al. CT073 - Pembrolizumab after two or more lines of prior therapy in patients with advanced small-cell lung cancer (SCLC): Results from the KEYNOTE-028 and KEYNOTE-158 studies [abstract]. AACR Annual Meeting. Atlanta, GA; 2019:Abstract CT073. Accessed November 8, 2021. Available at: https://cancerres.aacrjournals.org/content/79/13_Supplement/CT073.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 181.

    Ganti AKP, Loo BW, Bassetti M, et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Small Cell Lung Cancer (Version 2.2022). Evidence Blocks. © 2021 National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the NCCN Guidelines®, go online to NCCN.org. Available at: www.NCCN.org

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 182.

    Davies M, Duffield EA. Safety of checkpoint inhibitors for cancer treatment: strategies for patient monitoring and management of immune-mediated adverse events. ImmunoTargets Ther 2017;6:5171.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 183.

    Khunger M, Rakshit S, Pasupuleti V, et al. Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer: a systematic review and meta-analysis of trials. Chest 2017;152:271281.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 184.

    Yamamoto N, Tsurutani J, Yoshimura N, et al. Phase II study of weekly paclitaxel for relapsed and refractory small cell lung cancer. Anticancer Res 2006;26(1B):777781.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 185.

    Smit EF, Fokkema E, Biesma B, et al. A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer. Br J Cancer 1998;77:347351.

  • 186.

    von Eiff D, Bozorgmehr F, Chung I, et al. Paclitaxel for treatment of advanced small cell lung cancer (SCLC): a retrospective study of 185 patients. J Thorac Dis 2020;12:782793.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 187.

    Smyth JF, Smith IE, Sessa C, et al. Activity of docetaxel (Taxotere) in small cell lung cancer. Eur J Cancer 1994;30A:10581060.

  • 188.

    Masuda N, Fukuoka M, Kusunoki Y, et al. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 1992;10:12251229.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 189.

    Pietanza MC, Waqar SN, Krug LM, et al. Randomized, double-blind, phase II study of temozolomide in combination with either veliparib or placebo in patients with relapsed-sensitive or refractory small-cell lung cancer. J Clin Oncol 2018;36:23862394.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 190.

    Zauderer MG, Drilon A, Kadota K, et al. Trial of a 5-day dosing regimen of temozolomide in patients with relapsed small cell lung cancers with assessment of methylguanine-DNA methyltransferase. Lung Cancer 2014;86:237240.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 191.

    Baize N, Monnet I, Greillier L, et al. Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol 2020;21:12241233.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 192.

    Postmus PE, Berendsen HH, van Zandwijk N, et al. Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy. Eur J Cancer Clin Oncol 1987;23:14091411.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 193.

    Goto K, Ohe Y, Shibata T, et al. Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2016;17:11471157.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 194.

    Asai N, Ohkuni Y, Matsunuma R, et al. Efficacy and safety of amurubicin for the elderly patients with refractory relapsed small cell lung cancer as third-line chemotherapy. J Cancer Res Ther 2012;8:266271.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 195.

    Ettinger DS, Jotte R, Lorigan P, et al. Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer. J Clin Oncol 2010;28:25982603.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 196.

    Inoue A, Sugawara S, Yamazaki K, et al. Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402. J Clin Oncol 2008;26:54015406.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 197.

    Onoda S, Masuda N, Seto T, et al. Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301. J Clin Oncol 2006;24:54485453.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 198.

    Shimokawa T, Shibuya M, Kitamura K, et al. Retrospective analysis of efficacy and safety of amrubicin in refractory and relapsed small-cell lung cancer. Int J Clin Oncol 2009;14:6369.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 199.

    Jotte R, Conkling P, Reynolds C, et al. Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy. J Clin Oncol 2011;29:287293.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 200.

    von Pawel J, Jotte R, Spigel DR, et al. Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer. J Clin Oncol 2014;32:40124019.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 201.

    Petrelli F, Ghidini A, Luciani A. Topotecan or other agents as second-line therapy for relapsed small-cell lung cancer: A meta-analysis of randomized studies. Mol Clin Oncol 2021;15:218.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 202.

    Giaccone G, Ferrati P, Donadio M, et al. Reinduction chemotherapy in small cell lung cancer. Eur J Cancer Clin Oncol 1987;23:16971699.

  • 203.

    Genestreti G, Tiseo M, Kenmotsu H, et al. Outcomes of platinum-sensitive small-cell lung cancer patients treated with platinum/etoposide rechallenge: a multi-institutional retrospective analysis. Clin Lung Cancer 2015;16:e223e228.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation